Register or Login
All
  • All
  • Uniprot Id
  • Catalog #
  • Peptide Sequence
>   home   >   Products   >   Peptides   >   Blocking Peptides   >   LOH11CR2A Antibody (N-term) Blocking Peptide   

LOH11CR2A Antibody (N-term) Blocking Peptide

Synthetic peptide

     
  • SPECIFICATION
  • CITATIONS
  • PROTOCOLS
  • BACKGROUND
Product Information
Primary Accession O00534
Clone Names 81202077
Additional Information
Other Names von Willebrand factor A domain-containing protein 5A, Breast cancer suppressor candidate 1, BCSC-1, Loss of heterozygosity 11 chromosomal region 2 gene A protein, VWA5A, BCSC1, LOH11CR2A
Target/Specificity The synthetic peptide sequence used to generate the antibody AP8651a was selected from the N-term region of human LOH11CR2A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Format Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
StorageMaintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
PrecautionsThis product is for research use only. Not for use in diagnostic or therapeutic procedures.
Protein Information
Name VWA5A
Synonyms BCSC1, LOH11CR2A
Function May play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.
Tissue Location Expressed at low level in many tissues. Not expressed in 80% of tumor cell lines tested EMBL; AY366505; AAQ94873.1; -; mRNA EMBL; AY366508; AAQ94876.1; -; mRNA EMBL; AY366503; AAQ94871.1; -; mRNA EMBL; AY366506; AAQ94874.1; -; mRNA EMBL; AY366504; AAQ94872.1; -; mRNA EMBL; AY366507; AAQ94875.1; -; mRNA EMBL; AY366501; AAQ94867.1; -; Genomic_DNA EMBL; AY366501; AAQ94868.1; -; Genomic_DNA EMBL; AY366501; AAQ94869.1; -; Genomic_DNA EMBL; BT006655; AAP35301.1; -; mRNA EMBL; BC001234; AAH01234.1; -; mRNA EMBL; AF002672; AAB60942.1; -; mRNA CCDS; CCDS8444.1; -. [O00534-1] CCDS; CCDS8445.1; -. [O00534-3] RefSeq; NP_001123614.1; NM_001130142.1. [O00534-1] RefSeq; NP_055437.2; NM_014622.4. [O00534-1] RefSeq; NP_938057.1; NM_198315.2. [O00534-3] BioGRID; 110197; 36 IntAct; O00534; 33 STRING; 9606.ENSP00000407726; - iPTMnet; O00534; - PhosphoSitePlus; O00534; - BioMuta; VWA5A; - EPD; O00534; - jPOST; O00534; - MassIVE; O00534; - MaxQB; O00534; - PaxDb; O00534; - PeptideAtlas; O00534; - PRIDE; O00534; - ProteomicsDB; 47959; -. [O00534-1] ProteomicsDB; 47960; -. [O00534-2] ProteomicsDB; 47961; -. [O00534-3] ProteomicsDB; 47962; -. [O00534-4] Antibodypedia; 32857; 338 antibodies DNASU; 4013; - Ensembl; ENST00000361352; ENSP00000355070; ENSG00000110002. [O00534-3] Ensembl; ENST00000392748; ENSP00000376504; ENSG00000110002. [O00534-1] Ensembl; ENST00000449321; ENSP00000404683; ENSG00000110002. [O00534-3] Ensembl; ENST00000456829; ENSP00000407726; ENSG00000110002. [O00534-1] GeneID; 4013; - KEGG; hsa:4013; - UCSC; uc001pzr.4; human. [O00534-1] CTD; 4013; - DisGeNET; 4013; - EuPathDB; HostDB:ENSG00000110002.15; - GeneCards; VWA5A; - HGNC; HGNC:6658; VWA5A HPA; ENSG00000110002; Low tissue specificity MIM; 602929; gene neXtProt; NX_O00534; - OpenTargets; ENSG00000110002; - PharmGKB; PA162409005; - eggNOG; ENOG410IG85; Eukaryota eggNOG; COG2304; LUCA GeneTree; ENSGT00940000159961; - HOGENOM; CLU_003826_4_0_1; - InParanoid; O00534; - OMA; FNVIRFD; - OrthoDB; 955432at2759; - PhylomeDB; O00534; - TreeFam; TF329720; - BioGRID-ORCS; 4013; 1 hit in 790 CRISPR screens ChiTaRS; VWA5A; human GenomeRNAi; 4013; - Pharos; O00534; Tbio PRO; PR:O00534; - Proteomes; UP000005640; Chromosome 11 RNAct; O00534; protein Bgee; ENSG00000110002; Expressed in amniotic fluid and 211 other tissues ExpressionAtlas; O00534; baseline and differential Genevisible; O00534; HS GO; GO:0005654; C:nucleoplasm; IDA:HPA Gene3D; 3.40.50.410; -; 1 InterPro; IPR013694; VIT InterPro; IPR002035; VWF_A InterPro; IPR036465; vWFA_dom_sf Pfam; PF08487; VIT; 1 Pfam; PF13768; VWA_3; 1 SMART; SM00609; VIT; 1 SMART; SM00327; VWA; 1 SUPFAM; SSF53300; SSF53300; 1 PROSITE; PS51468; VIT; 1 PROSITE; PS50234; VWFA; 1 1: Evidence at protein level; Alternative splicing; Polymorphism; Reference proteome; Tumor suppressor CHAIN 1..786 /note="von Willebrand factor A domain-containing protein 5A" /id="PRO_0000084411" DOMAIN 1..131 /note="VIT" /evidence="ECO:0000255|PROSITE-ProRule:PRU00801" DOMAIN 281..462 /note="VWFA" /evidence="ECO:0000255|PROSITE-ProRule:PRU00219" VAR_SEQ 265..266 /note="SF -> RT (in isoform 4)" /evidence="ECO:0000303|PubMed:14504409" /id="VSP_013364" VAR_SEQ 267..786 /note="Missing (in isoform 4)" /evidence="ECO:0000303|PubMed:14504409" /id="VSP_013365" VAR_SEQ 389..426 /note="LFVFTDGEVTDTFSVIKEVRINRQKHRCFSFGIGEGTS -> VFERPYTLTV LLLHLSPEGNLCVIRPRHSRWTITVSVG (in isoform 2)" /evidence="ECO:0000303|PubMed:14504409" /id="VSP_013367" VAR_SEQ 416..786 /note="Missing (in isoform 3)" /evidence="ECO:0000303|PubMed:14504409, ECO:0000303|PubMed:15489334, ECO:0000303|Ref.2" /id="VSP_013366" VAR_SEQ 427..786 /note="Missing (in isoform 2)" /evidence="ECO:0000303|PubMed:14504409" /id="VSP_013368" VARIANT 202 /note="S -> G (in dbSNP:rs35496433)" /id="VAR_059692" VARIANT 205 /note="E -> K (in dbSNP:rs35215239)" /id="VAR_059693" VARIANT 499 /note="S -> I (in dbSNP:rs2276054)" /evidence="ECO:0000269|PubMed:9417908" /id="VAR_014193" VARIANT 506 /note="R -> K (in dbSNP:rs2276053)" /evidence="ECO:0000269|PubMed:9417908" /id="VAR_014194" VARIANT 757 /note="R -> C (in dbSNP:rs117689747)" /evidence="ECO:0000269|PubMed:9417908" /id="VAR_014195" VARIANT 759 /note="H -> R (in dbSNP:rs200614108)" /evidence="ECO:0000269|PubMed:9417908" /id="VAR_014196" SEQUENCE 786 AA; 86489 MW; 4CCD27B4B6DD9BD0 CRC64; MVHFCGLLTL HREPVPLKSI SVSVNIYEFV AGVSATLNYE NEEKVPLEAF FVFPMDEDSA VYSFEALVDG KKIVAELQDK MKARTNYEKA ISQGHQAFLL EGDSSSRDVF SCNVGNLQPG SKAAVTLKYV QELPLEADGA LRFVLPAVLN PRYQFSGSSK DSCLNVKTPI VPVEDLPYTL SMVATIDSQH GIEKVQSNCP LSPTEYLGED KTSAQVSLAA GHKFDRDVEL LIYYNEVHTP SVVLEMGMPN MKPGHLMGDP SAMVSFYPNI PEDQPSNTCG EFIFLMDRSG SMQSPMSSQD TSQLRIQAAK ETLILLLKSL PIGCYFNIYG FGSSYEACFP ESVKYTQQTM EEALGRVKLM QADLGGTEIL APLQNIYRGP SIPGHPLQLF VFTDGEVTDT FSVIKEVRIN RQKHRCFSFG IGEGTSTSLI KGIARASGGT SEFITGKDRM QSKALRTLKR SLQPVVEDVS LSWHLPPGLS AKMLSPEQTV IFRGQRLISY AQLTGRMPAA ETTGEVCLKY TLQGKTFEDK VTFPLQPKPD VNLTIHRLAA KSLLQTKDMG LRETPASDKK DALNLSLESG VISSFTAFIA INKELNKPVQ GPLAHRDVPR PILLGASAPL KIKCQSGFRK ALHSDRPPSA SQPRGELMCY KAKTFQMDDY SLCGLISHKD QHSPGFGENH LVQLIYHQNA NGSWDLNEDL AKILGMSLEE IMAAQPAELV DSSGWATILA VIWLHSNGKD LKCEWELLER KAVAWMRAHA GSTMPSVVKA AITFLKSSVD PAIFAF
Research Areas
Citations (0)

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.

Submit your citation using an Abcepta antibody to
info@abcepta.com, and receive a free "I Love Antibodies" mug.

Background

LOH11CR2A may play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.

References

Zhou,Y.Q., et.al., Cancer Sci. 100 (10), 1817-1822 (2009)

FeedBack
Abcepta welcomes feedback from its customers.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abcepta.com.

$ 277.78
Cat# BP8651a
Size:
Quantity:
Availability: 2 weeks
Bulk Size

Ordering Information

United States
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaCentral AmericaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSouth KoreaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamWorldwideOthers
Abcepta, Inc.
(888) 735-7227 / (858) 622-0099
(858) 622-0609
USA Headquarters
(888) 735-7227 / (858) 622-0099 or (858) 875-1900
Cedarlane Labs
+1 (800) 721-1644
+1 (336) 513-5138

Shipping Information

Domestic orders (in stock items)
Shipped out the same day. Orders placed after 1 PM (PST) will ship out the next business day.
International orders
Contact your local distributors
Terms & Conditions
"